FL molecular subgroups come of age

In this issue of Blood, Laurent et al dissect the heterogeneity of follicular lymphoma (FL) and present a new clinically applicable model that captures the biological diversity of the disease. 1 Several prognostic models, based either on gene expression or genetic features, have been proposed for FL. [2]][4] Although these can potentially aid in risk stratification for patients treated with rituximab-chemotherapy (R-chemo), they can be difficult to implement in routine practice and are rarely portable to other regimens.Also, although the available models can help identify patients with higher risk of progression or histologic transformation, none offer guidance for a specific treatment when deviating from standard of care.This represents a significant knowledge gap in the face of a growing number of promising treatment options.